RxDoctor Payments Data

Kristy Stokes

Family · Atlanta, GANPI 1154180925

Payments from drug & device makers

$4,172in general payments, 2019–2025

Across 172 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$476
  • Radius Health, Inc.$386
  • Novo Nordisk$363
  • Amgen$325
  • Sanofi-aventis U.S. LLC$321
  • Ascendis Pharma Endocrinology Inc$289
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,157100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,172 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$10,260
Medicare patients
93
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$88,914
OzempicSemaglutide48$58,587
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/720$17,401
JardianceEmpagliflozin13$15,016
Novolog FlexpenInsulin Aspart26$10,238
SynthroidLevothyroxine Sodium37$3,929
HumalogInsulin Lispro14$2,706
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$1,999
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$1,451
Liothyronine Sodium18$1,220
Levothyroxine Sodium61$921
Metformin Hcl ErMetformin Hcl15$342
Atorvastatin Calcium19$317
Rosuvastatin Calcium11$198
Metformin Hcl15$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humalog$476$91,62070 claims
Novo NordiskOzempic$363$58,58748 claims
Boehringer IngelheimJardiance$93$15,01613 claims
AbbVieSynthroid$34$3,92937 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$92161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →